Distinct response of experimental neuroblastoma to combination antiangiogenic strategies

Journal of Pediatric Surgery

Volumn 37, Issue 3, 2002, Pages 518-522

  Kim, Eugene S ^a,b,c   Soffer, Samuel Z ^a,b,c   Huang, Jianzhong ^a,b,c   McCrudden, Kimberly W ^a,b,c   Yokoi, Akiko ^a,b,c   Manley, Christina A ^a,b,c   Middlesworth, William ^a,b,c   Kandel, Jessica J ^a,b,c   Yamashiro, Darrell J ^a,b,c  

^a Columbia University ^*  (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Antiangiogenic therapy; Neuroblastoma; Topotecan; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; TOPOTECAN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL RATE; TUMOR GROWTH; VASCULARIZATION;

EID: 0036191974     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2002.30855     Document Type: Conference Paper

References (15)

1. Vascular endothelial growth factor is a secreted angiogenic mitogen
2. Vascular permeability factor (VPF, VEGF) in tumor biology
3. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
4. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor
5. All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor
6. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
7. Continuous low dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
8. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents
9. Combination anti-angiogenic therapy: Increased efficacy in a murine model of Wilms tumor
10. Campothecins: A review of their development and schedules of administration
11. Topotecan in pediatric patients and progressive solid tumors: A Pediatric Oncology Group phase II study
12. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
13. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents
14. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
15. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors